CNBC Recursion Pharm - Search Videos

Today, we announce our Q1 2026 business updates and financial results – demonstrating continued momentum across our internal portfolio and partnered programs, with multiple value-driving milestones on track.🚀 Key proof points include:▪️ REC-1245 (RBM39 degrader): Early clinical data demonstrate a well-tolerated safety profile and predictable, dose-dependent PK (n=16); dose escalation ongoing with no dose-limiting toxicities observed to date.▪️ REC-4539 (LSD1 inhibitor): First patient dosed in P

11.5K views2 weeks ago

Lightning round: Recursion Pharmaceuticals and NuScale Power

Lightning round: Recursion Pharmaceuticals and NuScale Power

Watch CNBC's full interview with Recursion CEO Chris Gibson

Watch CNBC's full interview with Recursion CEO Chris Gibson

CNBC PRO

Recursion CEO on $688M Exscientia acquisition: Hope to bring better medicines to patients sooner

Recursion CEO on $688M Exscientia acquisition: Hope to bring better medicines to patients sooner

Recursion CEO Chris Gibson talks integrating AI into drug development process

Recursion CEO Chris Gibson talks integrating AI into drug development process

Recursion Pharmaceuticals CEO Chris Gibson goes one-on-one with Jim Cramer

Recursion Pharmaceuticals CEO Chris Gibson goes one-on-one with Jim Cramer

Recursion CEO Chris Gibson: There's real opportunity to leverage A.I. to speed up drug development

Lightning Round: Recursion Pharma is now a meme stock, says Jim Cramer

We've built an unbiased platform that lets data drive decisions, not us, says Recursion CEO

'We look like what the future of all biopharma companies will look like', says Recursion CEO Gibson

Recursion CEO and President Najat Khan says the AI drug discovery industry is entering a new phase. “It’s no longer about what models you build or about what collaborations you sign,” she says. “It’s about what you unlock that can actually drive better medicines, and Recursion is firmly pioneering that new phase.” #TechBio #finance #earnings #AI #drugdiscovery | Recursion Pharmaceuticals

32.2K views2 months ago

FacebookRecursion Pharmaceuticals

Jensen Huang at Recursion: Enabling Leaders in AI Drug Discovery In a conversation with Recursion co-founder and CEO Chris Gibson, @nvidia president, co-founder and CEO Jensen Huang says there’s no harder problem than doing “drug discovery in silico” but it’s a problem that’s solvable in this lifetime. To solve it requires 3 key ingredients, Jensen says: 1) the algorithm 2) computing 3) methodology - “which in a large scale is kind of domain expertise” “We could contribute to two of those three

485.3K views8 months ago

FacebookRecursion Pharmaceuticals

🚀 Recursion has been laying the foundation for a virtual cell from day one – including massive-scale, proprietary biological and chemical datasets, AI models, and one of the industry’s most powerful supercomputers. 💥 In a new video and article we share our progress – and where we’re headed next: ▪️ It started with creating a proprietary data moat, generating and aggregating more than 65 petabytes of multimodal and fit-for-purpose data. ▪️ Then we built a system of interconnected AI models capa

62 views5 months ago

FacebookRecursion Pharmaceuticals

Valeant under pressure

Recursion Pharmaceuticals, Inc. annonce ses résultats pour le troisième trimestre et les neuf mois se terminant le 30 septembre 2024

Recursion Pharmaceuticals rises 13.1% after JP Morgan raises co to 'overweight' from 'neutral'

marketscreener.com

Recursion Pharmaceuticals Shares Rise After JPMorgan Upgrade

marketscreener.com

Gilead buys Kite for $11.9 billion

CNBCDavid Faber

Lightning Round: Reddit is 'fabulous', says Jim Cramer

FDA Head: Indonesia to compete in global drug testing

Recursion CEO Chris Gibson: There's real opportunity to leverage A.I. to speed up drug development - The Global Herald

theglobalherald.com

Lightning Round: Casey's General Store is a 'hidden gem', says Jim Cramer

Lightning Round: GameStop raised enough money to reinvent the company, says Jim Cramer

Lightning Round: I would not be a buyer of Corning all the way up here, says Jim Cramer

Lightning Round: ONEOK might be one of the best run pipeline companies, says Jim Cramer

Recursion Pharmaceuticals The Future of AI in Biotech

19 views2 months ago

YouTubeOrdinary investor

Recursion Pharmaceuticals Mystery: Why 715M loss? How to trade for profit 🔍

24 views4 months ago

YouTube불로불사 프로젝트

Recursion on Instagram: "▪️ 1 in 5 people will develop cancer. ▪️ 1 of 9 men and 1 of 12 women will die from cancer. ▪️ 90% of drugs that go into clinical trials fail. Statistics like these are what fuel all of us at Recursion to create a better way to make new medicines. A new episode of @google’s podcast Where the Internet Lives called “Mapping New Medicines” looks at the approach we’re taking – one that relies on massive proprietary datasets spanning biology, chemistry and patient data; super

3.8K views3 months ago

Instagramrecursionpharma

What Is An mRNA Coronavirus Vaccine?

937.9K viewsSep 19, 2020

See more